SARS-CoV-2 and myocardial injury: Few answers, many questions

Paul C. Cremer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Acute cardiac injury, defined as an elevated high-sensitivity troponin I or troponin T upon admission or during hospitalization, is common in patients with COVID-19, occurring in 10% to 35% of patients depending on the assay used and the population studied. Even though the mechanisms of SARS-CoV-2 myocardial injury are not well defined, type 1 myocardial infarction and fulminant myocarditis are rare. Often, acute cardiac injury occurs in patients with elevated inflammatory markers, and both are associated with worse outcomes. However, the extent to which treatments should differ for patients with acute cardiac injury, heightened systemic inflammation, or both, is unknown.

Original languageEnglish (US)
Pages (from-to)521-525
Number of pages5
JournalCleveland Clinic journal of medicine
Volume87
Issue number9
DOIs
StatePublished - Sep 2020

Keywords

  • and micro- and macrothrombosis. In some patients
  • microvascular and endothelial dysfunction
  • The mechanisms of acute cardiac injury in COVID-19 are still being defined but include oxygen supply-demand imbalance
  • these manifestations may be driven by an inappropriate inflammatory response

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'SARS-CoV-2 and myocardial injury: Few answers, many questions'. Together they form a unique fingerprint.

Cite this